Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Amicus Therapeutics, Inc. (FOLD): Redmile Group Trims Position and Books Some Profits from Long-Term Investment

Jeremy Green‘s Redmile Group has also reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD), after yesterday, William Leland Edwards’ Palo Alto Investors reported the sale of nearly a half of its stake in the company. However, Redmile only slightly reduced its exposure to the company, reporting ownership of around 7.36 million shares, versus 8.50 million held as of the end of June.

Amicus Therapeutics

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been in the equity portfolio of Redmile Group since the end of 2012, with the stock of the company surging by over 140% since then. Overall, Redmile Group has a concentrated equity portfolio which is almost completely focused on the healthcare sector.  Among other investors in Amicus is the aforementioned Palo Alto Networks, which owns 1.95 million shares following the latest disposal of shares. The largest shareholder, among those that we track, is Perceptive Advisors, led by Joseph Edelman, which owns some 12.34 million shares as of the end of June, after boosting its stake by around 1,100% during the second quarter. Moreover, Ken Greenberg and David Kim‘s Ghost Tree Capital added Amicus Therapeutics, Inc. (NASDAQ:FOLD) to its equity portfolio during the same period and owns 600,000 shares as of the end of June.

With being at the development stage of its products, Amicus has not been having any revenues so far, although the company managed to improve its net loss due to reduction of its expenses. For the second quarter, the company posted a net loss of $0.22, from $0.31 a year ago. The company is currently conducting Phase 3 studies for its product for Fabry disease. The results from the second study under the Phase 3 trial showed positive results, as Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced in August. On the back of these results, the stock of the company surged during the third quarter of the year.

Overall, Mr. Green has placed many profitable bets on companies from the healthcare sector. Redmile’s largest position is represented by Actavis plc (NYSE:ACT), which gained over 77% over the last 52 weeks. With the fund gaining significant profits over its long-term investments, Redmile fund is definitely a good source of insights from the healthcare sector.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!